.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Harvard Business School
US Army
Farmers Insurance
Cerilliant
Fuji
Deloitte
Baxter
Medtronic
Colorcon

Generated: December 14, 2017

DrugPatentWatch Database Preview

CLEVIPREX Drug Profile

« Back to Dashboard

When do Cleviprex patents expire, and what generic alternatives are available?

Cleviprex is a drug marketed by Chiesi Usa Inc and is included in one NDA. There are two patents protecting this drug.

This drug has sixty-one patent family members in thirty-three countries and six supplementary protection certificates in six countries.

The generic ingredient in CLEVIPREX is clevidipine. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the clevidipine profile page.

Summary for CLEVIPREX

Drug patent expirations by year for CLEVIPREX

Pharmacology for CLEVIPREX

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-001Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-002Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-001Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-002Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-003Nov 8, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-003Nov 8, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CLEVIPREX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-001Aug 1, 2008► Subscribe► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-003Nov 8, 2013► Subscribe► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-002Aug 1, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CLEVIPREX

Country Document Number Estimated Expiration
Finland110429► Subscribe
Australia2011313852► Subscribe
China1049428► Subscribe
China1137269► Subscribe
Norway305656► Subscribe
Japan2014196322► Subscribe
Greece3034469► Subscribe
Hungary215591► Subscribe
Portugal2627173► Subscribe
New Zealand275915► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CLEVIPREX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0726894/01Switzerland► SubscribePRODUCT NAME: RACEMISCHES CLEVIDIPINBUTYRAT; REGISTRATION NO/DATE: SWISSMEDIC 60117 11.06.2010
C0053France► SubscribePRODUCT NAME: CLEVIDIPINE; NAT. REGISTRATION NO/DATE: NL 37621 20120725; FIRST REGISTRATION: GB - PL 16881/0003 20111123
209Luxembourg► SubscribePRODUCT NAME: CLEVIDIPINE SOUS TOUTES LES FORMES PROCURANT UNE PROTECTION A PARTIR DU BREVET DE BASE
C/GB12/011United Kingdom► SubscribePRODUCT NAME: CLEVIDIPINE; REGISTERED: UK PL16881/0003 20111123
90008-0Sweden► SubscribePRODUCT NAME: CLEVIDIPINE; NAT. REG. NO/DATE: 42321 20120120; FIRST REG.: GB PL 16881/0003 20111123
00520Netherlands► SubscribePRODUCT NAME: CLEVIDIPINE; NAT. REGISTRATION NO/DATE: RVG 104771 20111129; FIRST REGISTRATION: PL 16881/0003 20111123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fish and Richardson
Cantor Fitzgerald
Julphar
Dow
US Department of Justice
Moodys
UBS
McKinsey
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot